Cara Therapeutics Current Ratio 2012-2021 | CARA

Cara Therapeutics current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cara Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.16B $0.02B 10.84
2021-03-31 $0.19B $0.02B 11.40
2020-12-31 $0.20B $0.02B 10.55
2020-09-30 $0.13B $0.02B 8.00
2020-06-30 $0.14B $0.03B 5.74
2020-03-31 $0.13B $0.03B 4.07
2019-12-31 $0.17B $0.04B 3.86
2019-09-30 $0.20B $0.05B 4.21
2019-06-30 $0.13B $0.04B 3.11
2019-03-31 $0.14B $0.04B 3.40
2018-12-31 $0.17B $0.04B 4.16
2018-09-30 $0.21B $0.04B 4.89
2018-06-30 $0.14B $0.04B 3.98
2018-03-31 $0.08B $0.01B 11.46
2017-12-31 $0.10B $0.01B 11.18
2017-09-30 $0.11B $0.01B 14.57
2017-06-30 $0.12B $0.01B 16.11
2017-03-31 $0.04B $0.01B 3.28
2016-12-31 $0.06B $0.01B 5.33
2016-09-30 $0.08B $0.01B 11.29
2016-06-30 $0.09B $0.01B 10.91
2016-03-31 $0.10B $0.01B 16.34
2015-12-31 $0.11B $0.01B 20.68
2015-09-30 $0.12B $0.00B 34.29
2015-06-30 $0.04B $0.00B 13.59
2015-03-31 $0.05B $0.00B 14.32
2014-12-31 $0.05B $0.00B 15.64
2014-09-30 $0.06B $0.01B 9.75
2014-06-30 $0.07B $0.01B 11.58
2014-03-31 $0.07B $0.01B 11.86
2013-12-31 $0.02B $0.01B 2.68
2013-09-30 $0.02B $0.01B 2.52
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2011-12-31 $0.01B $0.00B 1.56
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.783B $0.135B
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71